Dr. Yuanyuan Zhao 赵媛媛
Chief Physician
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical treatment of lung cancer and nasopharyngeal carcinoma, including chemotherapy, targeted therapy, immunotherapy, and clinical research on new drugs.
Dr. Zhao holds a doctoral degree and serves as an Associate Chief Physician and master's supervisor. Dr. Zhao was a visiting scholar at Montefiore Medical Center/Albert Einstein College of Medicine in the United States.
Professional roles
- Member, Cancer Rehabilitation and Palliative Care Professional Committee, Guangdong Anti-Cancer Association
- Standing Committee Member, Youth Committee of the Cancer Rehabilitation and Palliative Care Professional Committee, Guangdong Anti-Cancer Association
- Standing Committee Member, Youth Committee of the Chemotherapy Professional Committee, Guangdong Anti-Cancer Association
- Member, Guangdong Thoracic Disease Society
Name order: in Chinese the family name comes first (Zhao Yuanyuan). Papers usually list the name as Yuanyuan Zhao or Zhao Y.
Selected publications
154 papers on PubMed matched by name and affiliation; 21 as first or senior author since 2016. Most recent first- or senior-author papers:
- MedComm (2020), 2026 (senior author): Development and Validation of a Gene Expression-Based Prognostic Model for Patients With Small Cell Lung Cancer Treated With Chemotherapy. PubMed 42974076
- N Engl J Med, 2026 (first author): Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy. PubMed 42734213
- J Clin Oncol, 2026 (first author): Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study. PubMed 42497381
- J Immunother Cancer, 2026 (first author): DNA hypomethylation identifying clinical benefit subgroup of small-cell lung cancer: multi-omics analysis of a phase II trial with durvalumab plus olaparib as maintenance therapy. PubMed 42601174
- BMC Med, 2025 (first author): Pharmacokinetics, safety, and efficacy of mixed formulation of fosrolapitant and palonosetron (HR20013) in combination with dexamethasone in patients with solid tumors scheduled for highly emetogenic cisplatin-based chemotherapy: a phase I trial. PubMed 40866861
- J Inflamm Res, 2025 (senior author): A Novel Inflammation-Marker-Based Prognostic Model for Advanced Pulmonary Lymphoepithelioma-Like Carcinoma. PubMed 40008083
- Transl Lung Cancer Res, 2024 (senior author): Molecular subtypes and prognostic factors of lung large cell neuroendocrine carcinoma. PubMed 39430332
- Cell Rep Med, 2024 (first author): KN046, a bispecific antibody against PD-L1 and CTLA-4, plus chemotherapy as first-line treatment for metastatic NSCLC: A multicenter phase 2 trial. PubMed 38508135
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion